Live Analyst Rating Changes 1652 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Ritu Baral
TD
Ritu Baral
TD Cowen
Wall Street Analyst
★★☆☆☆
#2141
on 13Foresight · ranked by our own returns
38%
Success Rate
+8.6%
Average Return
21 of 55 calls profitable · -27.1% vs benchmark
📈 Across the calls we could measure, roughly 38% of Ritu Baral's ratings turned a profit when each position was held for 1 year — averaging +8.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

165 Buy 22 Hold 0 Sell
Ritu's Stock Coverage 54 ratings · 2026-06-22
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
KRYS
Krystal Biotech
 Jun 18, 2026 BUY Strong Buy
-28.2% avg upside
19 analysts
$403.00
15.83% Upside
 +0.0%
INSM
Insmed
 Jun 16, 2026 BUY Strong Buy
+82.2% avg upside
36 analysts
$243.00
153.70% Upside
 +3.1%
IVA
Inventiva
 Jun 09, 2026 BUY Strong Buy
+350.1% avg upside
16 analysts
$10.00
180.06% Upside
 -8.8%
FR:IVA
Inventiva
 Jun 08, 2026 BUY Strong Buy
+482.7% avg upside
5 analysts
$8.72
185.41% Upside
 ·
PRAX
Praxis Precision Medicines
 Jun 02, 2026 BUY Strong Buy
+91.5% avg upside
24 analysts
$510.00
80.58% Upside
 +4.6%
VERA
Vera Therapeutics
 Jun 02, 2026 BUY Strong Buy
+91.0% avg upside
19 analysts
 — +12.2%
BNTC
Benitec Biopharma
 May 14, 2026 BUY Buy
+118.1% avg upside
13 analysts
 — -3.0%
GHRS
GH Research
 May 14, 2026 BUY Strong Buy
+64.6% avg upside
11 analysts
 — -2.3%
VTVT
vTv Therapeutics
 May 14, 2026 BUY Strong Buy
-6.9% avg upside
12 analysts
$67.00
91.19% Upside
 -12.2%
MIST
Milestone Pharmaceuticals
 May 13, 2026 BUY Strong Buy
+537.4% avg upside
7 analysts
$8.00
515.41% Upside
 -24.4%
SION
Sionna Therapeutics, Inc.
 May 13, 2026 BUY Strong Buy
+44.5% avg upside
11 analysts
 — -13.5%
ANRO
Alto Neuroscience, Inc.
 May 13, 2026 BUY Strong Buy
+33.3% avg upside
13 analysts
 — -7.3%
ATAI
Atai Beckley N.V.
 May 13, 2026 BUY Strong Buy
+230.1% avg upside
16 analysts
 — -5.4%
CMPS
COMPASS Pathways
 May 13, 2026 BUY Strong Buy
+63.6% avg upside
18 analysts
$29.00
131.54% Upside
 +8.9%
NGNE
Neurogene
 May 13, 2026 BUY Buy
+55.5% avg upside
23 analysts
 — -15.0%
OVID
Ovid Therapeutics
 May 12, 2026 BUY Strong Buy
+109.1% avg upside
17 analysts
 — -8.4%
SGMT
Sagimet Biosciences, Inc. Class A
 May 12, 2026 BUY Strong Buy
+317.1% avg upside
15 analysts
$21.00
214.37% Upside
 -9.8%
PVLA
Palvella Therapeutics
 May 08, 2026 BUY Strong Buy
+45.3% avg upside
27 analysts
$267.00
136.02% Upside
 -6.8%
ACAD
ACADIA Pharmaceuticals
 May 07, 2026 BUY Strong Buy
+65.9% avg upside
42 analysts
$37.00
71.12% Upside
 -4.3%
SRPT
Sarepta Therapeutics
 May 07, 2026 HOLD Buy
+244.5% avg upside
49 analysts
$17.00
3.00% Downside
 -24.3%
MDGL
Madrigal Pharmaceuticals
 May 06, 2026 BUY Strong Buy
-5.8% avg upside
31 analysts
$644.00
27.40% Upside
 -6.3%
ALNY
Alnylam Pharma
 Apr 30, 2026 BUY Strong Buy
+23.6% avg upside
51 analysts
$482.00
73.35% Upside
 -8.6%
HELP
Helus Pharma
 Apr 13, 2026 BUY Strong Buy
+861.2% avg upside
12 analysts
$8.00
71.24% Upside
 ·
SPRO
Spero Therapeutics
 Nov 16, 2025 HOLD Buy
+501.5% avg upside
12 analysts
 — +15.2%
RLYB
Rallybio
 Nov 10, 2025 BUY Buy
+14.8% avg upside
8 analysts
 — +224.4%
SGMO
Sangamo Therapeutics
 Aug 11, 2025 BUY Buy
+5844.3% avg upside
16 analysts
 — -70.5%
TNYA
Tenaya Therapeutics
 Aug 11, 2025 BUY Strong Buy
+1268.7% avg upside
11 analysts
 — +26.5%
ANTX
AN2 Therapeutics, Inc.
 Apr 11, 2025 HOLD Buy
+75.0% avg upside
7 analysts
 — +132.0%
PLRX
Pliant Therapeutics
 Feb 18, 2025 BUY Buy
+1821.1% avg upside
21 analysts
 — -58.1%
SPRB
Spruce Biosciences
 Nov 23, 2021 HOLD Strong Buy
+90.7% avg upside
14 analysts
 — -58.5%
OZYMF
Orphazyme
 Jun 18, 2021 HOLD Hold
1 analyst
 — ·
TECX
Tectonic Therapeutic
 Mar 16, 2020 BUY Strong Buy
+87.9% avg upside
24 analysts
 — +34.3%
IONS
Ionis Pharmaceuticals
 Feb 27, 2020 HOLD Strong Buy
+13.3% avg upside
43 analysts
 — -1.7%
CBIO
Crescent Biopharma
 Feb 24, 2020 BUY Strong Buy
+26.9% avg upside
17 analysts
 — ·
SRRK
Scholar Rock Holding
 Aug 14, 2019 BUY Strong Buy
+20.1% avg upside
23 analysts
 — +24.4%
PTCT
PTC Therapeutics
 May 08, 2019 HOLD Buy
-1.5% avg upside
29 analysts
 — +15.0%
RARE
Ultragenyx Pharmaceutical
 Jan 06, 2019 BUY Strong Buy
+142.1% avg upside
36 analysts
 — -1.2%
QURE
uniQure
 Dec 03, 2018 BUY Strong Buy
+20.8% avg upside
29 analysts
 — +109.6%
TRVN
Trevena
 Oct 12, 2018 HOLD Buy
+128278.4% avg upside
11 analysts
 — ·
XFOR
X4 Pharmaceuticals
 Jul 02, 2018 HOLD Strong Buy
+491.4% avg upside
15 analysts
 — -35.7%
CYTK
Cytokinetics
 Apr 06, 2018 HOLD Strong Buy
+8.9% avg upside
36 analysts
 — +21.8%
ALDX
Aldeyra Therapeutics
 Apr 06, 2018 HOLD Strong Buy
+713.6% avg upside
21 analysts
 — +28.6%
VRDN
Viridian Therapeutics
 Apr 06, 2018 HOLD Strong Buy
+103.7% avg upside
32 analysts
 — -52.0%
MCRB
Seres Therapeutics
 Mar 16, 2017 BUY Buy
+162.3% avg upside
10 analysts
 — -29.3%
SVRA
Savara
 Dec 30, 2016 HOLD Strong Buy
+57.8% avg upside
17 analysts
 — +69.4%
TVRD
Tvardi Therapeutics
 May 15, 2014 BUY Buy
+585.4% avg upside
23 analysts
$29.00
1002.69% Upside
 -28.0%
BIIB
Biogen
 Jan 27, 2014 BUY Buy
+25.1% avg upside
51 analysts
$355.00
80.54% Upside
 +20.2%
AMRN
Amarin
 Nov 18, 2013 HOLD Buy
-47.3% avg upside
18 analysts
$1.60
90.04% Downside
 ·
XOMA
XOMA Royalty Corporation
 May 09, 2013 BUY Buy
-46.5% avg upside
11 analysts
$8.00
80.82% Downside
 -5.0%
ANTH
Anthera Pharmaceuticals
 Jul 09, 2012 BUY Buy
+472857042.9% avg upside
9 analysts
$3.00
299999900.09% Upside
 ·
PLX
Protalix
 Jun 25, 2012 HOLD Buy
+275.4% avg upside
4 analysts
$6.00
170.30% Upside
 -16.3%
TLPH
Talphera
 Jun 18, 2012 BUY Buy
+332.4% avg upside
15 analysts
$6.00
450.37% Upside
 +231.0%
OMER
Omeros
 Mar 14, 2012 BUY Buy
+111.2% avg upside
14 analysts
$13.00
26.56% Upside
 -45.5%
RMTI
Rockwell Med
 Feb 21, 2012 BUY Buy
+1445.1% avg upside
11 analysts
$14.00
2087.42% Upside
 -50.8%
🔒 49 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Ritu Baral — Frequently Asked Questions
How accurate are Ritu Baral's stock ratings?
Based on the calls 13Foresight could measure, about 38% of Ritu's ratings were profitable over a one-year hold, with an average return of +8.6% per rating, or -27.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Ritu ranked on 13Foresight?
Ritu Baral is currently ranked #2141 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Ritu cover?
Ritu most recently has ratings on KRYS, INSM, IVA, FR:IVA, PRAX, VERA, BNTC, GHRS, VTVT, MIST, SION, ANRO and 42 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.